24477-36-9

Basic information

• Product Name: N-{2-[4-(aminosulfonyl)phenyl]ethyl}-5-methyl-3-isoxazolecarboxamide
• Synonyms: N-{2-[4-(aminosulfonyl)phenyl]ethyl}-5-methyl-3-isoxazolecarboxamide
• CAS NO: 24477-36-9
• Molecular Formula: C₁₃H₁₅N₃O₄S
• Molecular Weight: 309.3409
• Mol File: 24477-36-9.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-{2-[4-(aminosulfonyl)phenyl]ethyl}-5-methyl-3-isoxazolecarboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-{2-[4-(aminosulfonyl)phenyl]ethyl}-5-methyl-3-isoxazolecarboxamide(24477-36-9)
• EPA Substance Registry System: N-{2-[4-(aminosulfonyl)phenyl]ethyl}-5-methyl-3-isoxazolecarboxamide(24477-36-9)

Safety Data

• Hazardous Substances Data: 24477-36-9(Hazardous Substances Data)

Usage

Description

N-2-[4-(aminosulfonyl)phenyl]ethyl-5-methyl-3-isoxazolecarboxamide is a chemical compound with a complex structure, characterized by its isoxazole and phenyl rings connected through an ethyl chain. It is a reagent used in the synthesis of various pharmaceutical compounds.

Uses

Used in Pharmaceutical Industry:
N-2-[4-(aminosulfonyl)phenyl]ethyl-5-methyl-3-isoxazolecarboxamide is used as a reagent for the synthesis of glisoxepid (G410600), an antidiabetic drug. It plays a crucial role in the development of medications for the treatment of diabetes mellitus type 2.
Glisixepid, synthesized using N-2-[4-(aminosulfonyl)phenyl]ethyl-5-methyl-3-isoxazolecarboxamide, is a sulfonylurea derivative that helps in managing blood sugar levels in patients with type 2 diabetes. It works by stimulating the release of insulin from the pancreas, thereby improving the body's ability to regulate glucose levels.

Upstream product

• 3405-77-4 5-methylisoxazole 3-carboxylic acid 
• 39499-34-8 5-methyl-3-isoxazolyl chloride 
• 35303-76-5 4-(2-aminoethyl)benzenesulfonamide 
• 25046-79-1 glisoxepide 
• 85-44-9 phthalic anhydride 
• 6325-22-0 chlorhydrate de (β-aminoethyl)-4 benzenesulfonamide 

Downstream Products

• 25046-83-7 5-methyl-isoxazole-3-carboxylic acid 4-[(3-methyl-1,1-dioxo-1λ⁶-thiomorpholin-4-ylcarbamoyl)-sulfamoyl]-phenethylamide 
• 25046-82-6 5-methyl-isoxazole-3-carboxylic acid 4-(morpholin-4-ylcarbamoyl-sulfamoyl)-phenethylamide 
• 25174-70-3 5-methyl-isoxazole-3-carboxylic acid 4-(piperidin-1-ylcarbamoyl-sulfamoyl)-phenethylamide 
• 24489-17-6 5-methyl-isoxazole-3-carboxylic acid 4-[(2-cyclohexyl-ethylcarbamoyl)-sulfamoyl]-phenethylamide 
• 24489-24-5 3-aza-bicyclo[3.2.2]nonane-3-carboxylic acid 4-[2-(5-methyl-isoxazole-3-carbonylamino)-ethyl]-benzenesulfonylamide 
• 24489-15-4 5-methyl-isoxazole-3-carboxylic acid 4-(cyclooctylcarbamoyl-sulfamoyl)-phenethylamide 
• 24489-23-4 2-aza-bicyclo[2.2.2]octane-2-carboxylic acid 4-[2-(5-methyl-isoxazole-3-carbonylamino)-ethyl]-benzenesulfonylamide 
• 25046-79-1 glisoxepide 
• 24489-22-3 4-methyl-piperazine-1-carboxylic acid 4-[2-(5-methyl-isoxazole-3-carbonylamino)-ethyl]-benzenesulfonylamide 
• 24489-14-3 5-methyl-isoxazole-3-carboxylic acid 4-(cycloheptylcarbamoyl-sulfamoyl)-phenethylamide 
• 24489-21-2 morpholine-4-carboxylic acid 4-[2-(5-methyl-isoxazole-3-carbonylamino)-ethyl]-benzenesulfonylamide 
• 24489-20-1 azepane-1-carboxylic acid 4-[2-(5-methyl-isoxazole-3-carbonylamino)-ethyl]-benzenesulfonylamide 
• 24489-19-8 piperidine-1-carboxylic acid 4-[2-(5-methyl-isoxazole-3-carbonylamino)-ethyl]-benzenesulfonylamide 
• 24489-03-0 5-methyl-isoxazole-3-carboxylic acid 4-(cyclopentylcarbamoyl-sulfamoyl)-phenethylamide 

Relevant articles and documents

NOVEL COMPOUNDS AND USES

The present invention relates to compounds of formula (I): wherein Q is O or S; R1 is a cyclic group substituted with at least one group X, wherein R1 may optionally be further substituted; X is any group comprising a carbonyl group; and R2 is a cyclic group substituted at the α-position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the dual action of NLRP3 inhibition and the stimulation of insulin secretion.

SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME

ABSTRACT The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.

Degradation of oral antidiabetics, I: Reactions of arylsulfonylureas with carboxylic acid

-